Aristo Bio-Tech Key Ratios
NSE: ARISTO
₹107.00
₹0.00 (0.00%)As on 28-Aug-2026 11:21IST
Market cap
₹73 Cr
Revenue (TTM)
₹318 Cr
P/E Ratio
10.1
P/B Ratio
2
Div. Yield
0.6 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 29.76 | 24.27 | 9.59 |
| EBIT | -- | -- | -2.77 | 17.86 | 10.83 |
| Net Profit | -- | -- | 4.30 | 41.51 | 32.17 |
| EPS | -- | -- | 4.30 | 27.63 | 24.23 |
| Book Value | -- | -- | 11.08 | 22.59 | 17.36 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 2.73 | 2.56 | 2.10 | 2.80 | 3.29 |
| Net Margin
| 1.50 | 1.20 | 1.27 | 1.59 | 1.63 |
| Return on equity
| 13.17 | 11.61 | 11.46 | 12.22 | 15.82 |
| Return on Capital
| 14.16 | 13.04 | 12.96 | 13.41 | 16.11 |
| Return on Assets
| 3.50 | 2.71 | 3.03 | 3.43 | 4.03 |
| Debt to Equity (x)
| -- | -- | 0.59 | 0.62 | 0.75 |
Profitability
ROCE
12.96
Higher than Peers by 0.73
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
12.96
|
13.41
|
16.11
|
11.43
|
11.27
|
|
Peer Median
|
12.22
|
21.63
|
27.13
|
26.41
|
--
|
ROE
11.46
Higher than Peers by 2.22
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
11.46
|
12.22
|
15.82
|
10.15
|
8.38
|
|
Peer Median
|
9.23
|
18.08
|
23.65
|
21.83
|
--
|
ROA
3.03
Lower than Peers by 2.95
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
3.03
|
3.43
|
4.03
|
1.81
|
1.27
|
|
Peer Median
|
5.98
|
9.92
|
11.99
|
10.73
|
--
|
EBIT Margin
2.10
Lower than Peers by 7.58
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
2.10
|
2.80
|
3.29
|
2.46
|
2.15
|
|
Peer Median
|
9.68
|
7.64
|
15.61
|
14.45
|
--
|
Net Margin
1.27
Lower than Peers by 4.36
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
1.27
|
1.59
|
1.63
|
0.86
|
0.64
|
|
Peer Median
|
5.63
|
8.97
|
12.29
|
11.31
|
--
|
Cash Profit Margin
2.10
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
2.10
|
2.23
|
2.34
|
1.53
|
0.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
29.76
Higher than Peers by 22.04
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
29.76
|
12.53
|
31.43
|
-0.87
|
-16.90
|
|
Peer Median
|
7.71
|
-11.85
|
28.76
|
12.22
|
--
|
EBIT Growth
-2.77
Lower than Peers by 34.33
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
-2.77
|
-4.25
|
75.86
|
13.34
|
-9.87
|
|
Peer Median
|
31.57
|
-36.92
|
24.92
|
27.46
|
--
|
Net Profit Growth
4.30
Lower than Peers by 26.29
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
4.30
|
9.36
|
148.44
|
33.29
|
6.78
|
|
Peer Median
|
30.59
|
-41.41
|
25.31
|
37.91
|
--
|
EPS Growth
4.30
Lower than Peers by 26.77
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
4.30
|
9.36
|
82.29
|
33.29
|
6.78
|
|
Peer Median
|
31.07
|
-42.07
|
26.92
|
38.53
|
--
|
Book Value Growth
11.08
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
11.08
|
11.45
|
102.85
|
11.10
|
8.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.59
Higher than Peers by 0.53
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
0.59
|
0.62
|
0.75
|
1.71
|
1.66
|
|
Peer Median
|
0.05
|
0.11
|
0.09
|
0.09
|
--
|
Short term debt to equity ratio
0.29
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
0.29
|
0.23
|
0.33
|
0.85
|
0.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.21
Lower than Peers by 0.86
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
1.21
|
1.26
|
1.39
|
1.23
|
1.23
|
|
Peer Median
|
2.07
|
1.63
|
1.80
|
1.85
|
--
|
Quick Ratio
0.72
Lower than Peers by 0.52
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
0.72
|
0.78
|
0.87
|
0.75
|
0.66
|
|
Peer Median
|
1.23
|
1.13
|
0.96
|
1.23
|
--
|
Interest Coverage
3.88
Lower than Peers by 8.34
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
3.88
|
4.05
|
2.72
|
1.84
|
1.65
|
|
Peer Median
|
12.22
|
12.03
|
32.38
|
25.98
|
--
|
Operating Efficiency
Debtors to sales
17.66
Lower than Peers by 12.88
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
17.66
|
23.44
|
20.46
|
20.03
|
19.59
|
|
Peer Median
|
30.54
|
25.72
|
30.34
|
28.66
|
--
|
Asset Turnover
2.37
Higher than Peers by 1.53
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
2.37
|
2.16
|
2.46
|
2.09
|
2.32
|
|
Peer Median
|
0.85
|
0.88
|
1.09
|
1.14
|
--
|
Receivable days
65.21
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
65.21
|
75.97
|
65.15
|
72.63
|
75.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
50.23
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
50.23
|
52.83
|
46.19
|
61.99
|
52.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
91.34
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
91.34
|
92.70
|
75.14
|
91.29
|
92.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
24.11
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
24.11
|
36.10
|
36.20
|
43.33
|
35.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
19.47
Lower than Peers by 20.34
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
19.47
|
10.91
|
10.71
|
--
|
--
|
|
Peer Median
|
39.81
|
50.05
|
19.11
|
27.36
|
--
|
Price / Book Value
2.12
Lower than Peers by 2.48
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
2.12
|
1.27
|
1.27
|
--
|
--
|
|
Peer Median
|
4.60
|
3.48
|
3.99
|
5.38
|
--
|
Dividend Yield
0.43
Higher than Peers by 0.23
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
0.43
|
0.64
|
0.45
|
--
|
--
|
|
Peer Median
|
0.20
|
0.55
|
0.35
|
0.25
|
--
|
EV/EBITDA
10.02
Lower than Peers by 19.14
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
10.02
|
7.17
|
6.51
|
5.52
|
5.95
|
|
Peer Median
|
29.16
|
19.72
|
17.29
|
22.13
|
--
|
Market Cap
79
Lower than Peers by 4,076
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Aristo Bio-Tech
|
79
|
43
|
38
|
--
|
--
|
|
Peer Median
|
4,155
|
3,052
|
3,521
|
3,428
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
